Nanoform Finland Oyj 관리

관리 기준 확인 2/4

Nanoform Finland Oyj CEO는 Edward Haeggstrom, Jan2015 에 임명되었습니다 의 임기는 9.83 년입니다. 는 € 8.64M 가치에 해당하는 회사 주식의 6.32% 직접 소유합니다. 8.64M. 경영진과 이사회의 평균 재임 기간은 각각 5.8 년과 5.4 년입니다.

주요 정보

Edward Haeggstrom

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	9.8yrs
CEO 소유권	6.3%
경영진 평균 재임 기간	5.8yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Jan 25

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Dec 21

CEO

Edward Haeggstrom (55 yo)

9.8yrs

테뉴어

Prof. Edward Olof Haeggstrom is a Co-Founder of Nanoform Finland Oy and has been its Chief Executive Officer since 2015. Prof. Haeggstrom is Scientific Advisor and the Chairman of the Board of Directors of...

리더십 팀

이름	위치	테뉴어	보상	소유권
Albert Haeggstrom	CFO & Director	6.8yrs	€80.37k	0.83% € 1.1m
Edward Haeggstrom	Co-Founder & CEO	9.8yrs	데이터 없음	6.32% € 8.6m
Henri von Haartman	Director of Investor Relations	no data	데이터 없음	데이터 없음
Peter Hanninen	General Counsel & Chief Development Officer	4.2yrs	데이터 없음	0.12% € 164.8k
David Rowe	Head of Manufacturing	5.8yrs	데이터 없음	데이터 없음
Christian Jones	Chief Commercial Officer	6.8yrs	데이터 없음	0.45% € 613.6k
Antonio Da Silva	Chief of Business Operations	1.8yrs	데이터 없음	0.029% € 39.1k
Johanna Kause	Chief Quality Officer	1.2yrs	데이터 없음	데이터 없음
Jamie Unwin	Vice President of Strategic Insight	no data	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: NANOFH 의 관리팀은 노련하고 경험 (평균 재직 기간 5.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Albert Haeggstrom	CFO & Director	9.8yrs	€80.37k	0.83% € 1.1m
Miguel Calado	Independent Chairman of the Board	5.7yrs	€94.50k	0.076% € 103.6k
Jeanne Thoma	Independent Director	3yrs	€58.51k	0.026% € 35.8k
Mads Laustsen	Independent Vice Chairman of the Board	5.2yrs	€58.51k	0.026% € 35.8k

5.4yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: NANOFH 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Nanoform Finland Oyj 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

Recent updates

Consensus revenue estimates fall by 42%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Market cap size

New minor risk - Share price stability

Price target decreased by 9.1% to €4.00

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

First quarter 2024 earnings released: €0.09 loss per share (vs €0.06 loss in 1Q 2023)

New minor risk - Shareholder dilution

Nanoform Finland Oyj has filed a Follow-on Equity Offering.

Consensus revenue estimates decrease by 21%, EPS upgraded

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

New minor risk - Profitability

Nanoform Finland plc Receives Positive Results from its Own Pre- Clinical, In-Vivo Study of a Nanocrystalline-Enabled Apalutamide Oral Formulation

New major risk - Share price stability

Nanoform Announces Important Milestone with Promising Clinical Results for Patient-Centric Nanotechnology-Enhanced Enzalutamide

Nanoform Finland plc Commences Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Forecast to breakeven in 2026

Nanoform Finland Oyj to Report Nine Months, 2024 Results on Nov 22, 2024

Consensus revenue estimates fall by 31%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think Nanoform Finland Oyj (HEL:NANOFH) Can Afford To Drive Business Growth

Consensus revenue estimates fall by 31%

No longer forecast to breakeven

Price target decreased by 16% to €6.00

Consensus revenue estimates decrease by 18%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Finnish Medicines Agency Renews Nanoform's GMP License and Nanoform Starts Clinical API Manufacturing of Blockbuster Medicine Candidate

We're Not Very Worried About Nanoform Finland Oyj's (HEL:NANOFH) Cash Burn Rate

Consensus revenue estimates fall by 37%

Price target decreased by 9.6% to €8.28

Forecast to breakeven in 2025

Nanoform Finland Oyj CTO Niklas Sandler Transitions to Technology Advisor to the CEO, effective, January 1, 2023

Nanoform Finland Oyj to Report Q3, 2023 Results on Nov 22, 2023

Nanoform Finland Oyj, Annual General Meeting, Apr 12, 2023

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Nanoform Finland Oyj (HEL:NANOFH) Will Use Its Cash Wisely

Consensus revenue estimates fall by 29%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform's Gonçalo Andrade Steps Down as Chief of Business Operations

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Nanoform Finland Plc. Launches "STARMAP® Online" Placing AI-Power at the Fingertips of Medicine Developers

Consensus forecasts updated

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nanoform signs GMP manufacturing program with TargTex following formulation success

Companies Like Nanoform Finland Oyj (HEL:NANOFH) Are In A Position To Invest In Growth

Consensus revenue estimates fall to €2.05m

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Second quarter 2021 earnings released: €0.07 loss per share (vs €0.14 loss in 2Q 2020)

First quarter 2021 earnings released: €0.06 loss per share (vs €0.12 loss in 1Q 2020)

Director has left the company

Nanoform Announces Completion and Final Results of Clinical Study

Nanoform Finland Oyj has completed a Follow-on Equity Offering in the amount of €40.000001 million.

Nanoform Finland Oyj to Report Q1, 2021 Results on May 27, 2021

Nanoform Finland Announces Further Positive Interim Results from Its Ongoing Clinical Study

New 90-day high: €7.73

New 90-day high: €7.40

Nanoform's Clinical Study Indicates Positive Interim Results

Nanoform Finland plc Announces First Dosing of Nanoformed Drug Successfully Accomplished

What You Need To Know About Nanoform Finland Oyj's (HEL:NANOFH) Investor Composition

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

New 90-day high: €4.59

Nanoform Launches Technology for Biologics and Sets New Near-Term Business Target for 2021

Nanoform Finland Oyj to Report Q3, 2020 Results on Nov 27, 2020

New 90-day low: €3.91

First half earnings released

CEO

테뉴어

리더십 팀